Close



Jul 5, 2022 07:18AM
Jul 5, 2022 07:15AM
Jun 22, 2022 04:35PM
Jun 8, 2022 04:40PM
Jun 8, 2022 04:25PM
May 25, 2022 07:57AM
May 25, 2022 07:55AM CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
May 25, 2022 07:47AM
May 25, 2022 07:45AM
Apr 28, 2022 07:57AM
Apr 28, 2022 07:50AM
Apr 22, 2022 07:15AM
Apr 21, 2022 07:16AM
Apr 21, 2022 07:15AM CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
Apr 11, 2022 07:17AM
Apr 11, 2022 07:15AM
Mar 30, 2022 07:17AM
Mar 30, 2022 07:15AM
Mar 1, 2022 07:19AM
Mar 1, 2022 07:15AM
Feb 10, 2022 07:20AM CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
Jan 18, 2022 05:27AM
Jan 17, 2022 07:15AM
Nov 19, 2021 02:00AM
Nov 18, 2021 06:12AM
Nov 18, 2021 06:10AM
Oct 12, 2021 07:17AM
Oct 12, 2021 07:15AM CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
Sep 14, 2021 07:32AM
Sep 14, 2021 07:30AM
Aug 31, 2021 03:08PM
Aug 31, 2021 07:15AM
Aug 30, 2021 11:58AM
Aug 30, 2021 07:15AM
Aug 16, 2021 10:40AM CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
Jul 1, 2021 09:30AM
Jun 30, 2021 05:52PM
Jun 30, 2021 04:45PM
Jun 30, 2021 07:12AM
Jun 25, 2021 12:35AM
Jun 23, 2021 07:45AM
Jun 16, 2021 05:00PM CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
Jun 2, 2021 07:30AM
May 26, 2021 07:30AM
May 13, 2021 07:49AM
May 13, 2021 07:45AM
Apr 15, 2021 07:45AM
Apr 9, 2021 07:35AM
Mar 23, 2021 08:20AM CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
Mar 22, 2021 08:17AM

99,418 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All